

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6907104

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AERPIO PHARMACEUTICALS, INC.	08/26/2021

RECEIVING PARTY DATA

Name:	EYEPOINT PHARMACEUTICALS, INC.
Street Address:	480 PLEASANT STREET, SUITE A-210
City:	WATERTOWN
State/Country:	MASSACHUSETTS
Postal Code:	02472

PROPERTY NUMBERS Total: 133

Property Type	Number
Application Number:	60816730
Application Number:	60816731
Application Number:	60816825
Patent Number:	7622593
Patent Number:	7795444
Patent Number:	7589212
Patent Number:	8258311
Patent Number:	8338615
Patent Number:	8946232
Patent Number:	8895563
Patent Number:	8329916
Patent Number:	9126958
Patent Number:	9284285
Patent Number:	9795594
Patent Number:	10463650
Application Number:	16577808
Application Number:	17096548
Application Number:	12558169
Patent Number:	8106078
Patent Number:	8188125

PATENT

Property Type	Number
Application Number:	13626590
Patent Number:	8846685
Patent Number:	RE46592
Application Number:	61144022
Application Number:	61184986
Application Number:	14075809
Application Number:	15443353
Application Number:	16719317
Application Number:	15930583
Application Number:	13968269
Patent Number:	9096555
Application Number:	12677512
Application Number:	61223260
Patent Number:	8883832
Patent Number:	9174950
Patent Number:	9949956
Application Number:	15913392
Application Number:	16582619
Application Number:	61390899
Application Number:	13253397
Application Number:	14300385
Application Number:	15462326
Application Number:	16513103
Application Number:	17352698
Application Number:	15796293
Application Number:	61792679
Application Number:	61792868
Application Number:	61882048
Application Number:	61882056
Application Number:	61934570
Patent Number:	9440963
Application Number:	14214413
Application Number:	15098955
Application Number:	15099161
Patent Number:	10220048
Application Number:	15443622
Application Number:	15958346
Application Number:	15958355

Property Type	Number
Application Number:	15958358
Application Number:	15969109
Application Number:	16257287
Application Number:	16559006
Application Number:	16888247
Application Number:	17155463
Application Number:	61953680
Patent Number:	9994560
Patent Number:	10858354
Application Number:	17062098
Application Number:	62019002
Application Number:	62190871
Application Number:	62361703
Application Number:	62222481
Patent Number:	10952992
Application Number:	17150430
Application Number:	62635102
Application Number:	62790646
Application Number:	16284349
Application Number:	17130687
Application Number:	62835626
Application Number:	62840655
Application Number:	16850613
Application Number:	62865653
Application Number:	63009083
Application Number:	16908996
Application Number:	62927233
Application Number:	17082612
Application Number:	62840068
Application Number:	16860347
Application Number:	62958348
Application Number:	63089144
Application Number:	17143394
Application Number:	63127412
Application Number:	63127411
Application Number:	63028317
Application Number:	60790506
Application Number:	60798896

Property Type	Number
Patent Number:	7973142
Patent Number:	9926367
Application Number:	15894442
Application Number:	16696212
Application Number:	16784970
Patent Number:	8524235
Application Number:	13958990
Application Number:	61546708
Patent Number:	8999325
Application Number:	14627463
Patent Number:	10329357
Application Number:	16395972
Application Number:	16751824
Application Number:	61546697
Application Number:	61546748
Application Number:	13652203
Patent Number:	10150811
Patent Number:	10815300
Application Number:	17027034
Application Number:	62054752
Application Number:	14862948
Application Number:	15815097
Application Number:	62364381
Application Number:	62377072
Patent Number:	10253094
Patent Number:	10604569
Patent Number:	10597452
Application Number:	16775860
Application Number:	16851420
Application Number:	62735331
Application Number:	62832461
Patent Number:	10894824
Application Number:	17117993
Patent Number:	8569348
Application Number:	62034695
Patent Number:	9539245
Application Number:	15365186

CORRESPONDENCE DATA**Fax Number:** (650)493-6811*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Email:** patentdocket@wsgr.com, rgallo@wsgr.com**Correspondent Name:** WILSON SONSINI GOODRICH & ROSATI**Address Line 1:** 650 PAGE MILL ROAD**Address Line 4:** PALO ALTO, CALIFORNIA 94304-1050

ATTORNEY DOCKET NUMBER:	61881
NAME OF SUBMITTER:	CARMEN CHOW
SIGNATURE:	/Carmen Chow/
DATE SIGNED:	09/09/2021

Total Attachments: 60

source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page1.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page2.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page3.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page4.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page5.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page6.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page7.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page8.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page9.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page10.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page11.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page12.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page13.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page14.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page15.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page16.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page17.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page18.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page19.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page20.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page21.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page22.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page23.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page24.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page25.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page26.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page27.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page28.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page29.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page30.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page31.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page32.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page33.tif

source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page34.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page35.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page36.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page37.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page38.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page39.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page40.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page41.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page42.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page43.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page44.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page45.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page46.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page47.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page48.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page49.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page50.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page51.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page52.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page53.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page54.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page55.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page56.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page57.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page58.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page59.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page60.tif

EXHIBIT D

PATENT ASSIGNMENT

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number 45725-700

Aerpio Pharmaceuticals, Inc., a corporation of the State of Delaware, having a place of business at 9987 Carver Road, Suite 420, Cincinnati, Ohio 45242, (the "Assignor"), desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to **EyePoint Pharmaceuticals, Inc.**, a corporation incorporated under the laws of the of Delaware, having a place of business at 480 Pleasant Street, Suite A-210, Watertown, MA 02472, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s) listed in **ATTACHMENTS A, B, and C** (the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.


3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, derivation proceedings, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.


4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor, its successors and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith, and that Assignor's predecessors have not entered into any assignment, contract or understanding in conflict herewith.

6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE PATENT ASSIGNMENT		Docket Number 45725-700
IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:		
AGREED TO BY ASSIGNOR: Aerpio Pharmaceuticals, Inc.		
Date: August 26, 2021	Signature: 	DocuSigned by: 678F00A134E4486...
	Name: Neil Desai	Title: Authorized Signatory
RECEIVED AND AGREED TO BY ASSIGNEE: EyePoint Pharmaceuticals, Inc.		
Date: August 26, 2021	Signature: Name: George Elston Title: Chief Financial Officer and Head of Corporate Development	

CORPORATE TO CORPORATE PATENT ASSIGNMENT		Docket Number 45725-700
IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:		
AGREED TO BY ASSIGNOR: Aerpio Pharmaceuticals, Inc.		
Date: August 26, 2021	Signature: Name: Neil Desai Title: Authorized Signatory	
RECEIVED AND AGREED TO BY ASSIGNEE: EyePoint Pharmaceuticals, Inc.		
Date: August 26, 2021	DocuSigned by:  Signature: Name: George Elston Title: Chief Financial Officer and Head of Corporate Development	

ATTACHMENT A

Country	Application No.	Filing Date	Patent No.	Patent Date	Title
United States	60/816,730	06/27/2006			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	60/816,731	06/27/2006			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	60/816,825	06/27/2006			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	11/823,086	06/26/2007	7,622,593	11/24/2009	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	11/821,846	06/26/2007	7,795,444	09/14/2010	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	11/821,868	06/26/2007	7,589,212	09/15/2009	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	12/624,072	11/23/2009	8,258,311	09/04/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/309,452	12/01/2011	8,338,615	12/25/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/691,757	12/01/2012	8,946,232	02/03/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/936,450	07/08/2013	8,895,563	11/25/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/309,445	12/01/2011	8,329,916	12/11/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	14/569,106	12/12/2014	9,126,958	09/08/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

United States	14/252,140	04/14/2014	9,284,285	03/15/2016	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	15/016,599	02/05/2016	9,795,594	10/24/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	15/705,639	09/15/2017	10,463,650	11/05/2019	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	16/577,808	09/20/2019			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	17/096,548	11/12/2020			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	12/558,169	09/11/2009			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	12/850,026	08/04/2010	8,106,078	01/31/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	12/467,430	05/18/2009	8,188,125	05/29/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/626,590	09/25/2012			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/626,614	09/25/2012	8,846,685	09/30/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	14/938,526	11/11/2015	RE46,592	10/31/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
WO	PCT/US2007/0148 22	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
WO	PCT/US2007/0148 23	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
WO	PCT/US2007/0148 24	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Europe	7809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	12196179.1	06/27/2007	2592073	08/30/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	17187910.9	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe	17182516.9	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany	12196174.2	06/27/2007	602007052457.1	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany	602007052232.3	06/27/2007	2592073	08/30/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany	602007053259.0	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Germany	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	12196179.1	06/27/2007	2592073	08/30/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France	7809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom	12196179.1	06/27/2007	2592073	08/30/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
United Kingdom	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria	14166121.5	06/27/2007	2803663	11/29/2007	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium	07809909.0	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Belgium	07809907.4	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Bulgaria	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Bulgaria	7809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Bulgaria	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Lithuania	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Lithuania	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Lithuania	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Latvia	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Latvia	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Latvia	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	7809909	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	7809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Switzerland	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	14166121.5	06/27/2007	2803663	11/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Denmark	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Finland	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Greece	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Greece	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Greece	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hungary	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hungary	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hungary	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Iceland	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Iceland	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Iceland	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Ireland	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland	12196179.1	06/27/2007	2592073	08/30/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	12196179.1	06/27/2007	2592073	08/30/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Luxembourg	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg	7809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Netherlands	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Romania	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Romania	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Romania	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden	17191765.1	06/27/2007	3323815	10/07/2020	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovenia	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovenia	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovenia	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovakia	07809909.0	06/27/2007	2041129	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Slovakia	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovakia	07809908.2	06/27/2007	2038265	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey	07809909.0	06/27/2007	TR 2014 12834 T4	09/03/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey	07809907.4	06/27/2007	2041102	11/12/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey	07809908.2	06/27/2007	TR 2015 04305 T4	03/18/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey	12196174.2	06/27/2007	2592072	09/20/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey	14166121.5	06/27/2007	2803663	11/29/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia	2007265453	06/27/2007	2007265453	05/03/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia	2007265454	06/27/2007	2007265454	02/09/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia	2007265455	06/27/2007	2007265455	02/23/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia	2012200253	06/27/2007	2012200253	10/18/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Brazil	PI 0713570-0	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Brazil	PI 0713357-0	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Brazil	PI 0713349-9	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Canada	2,657,096	06/27/2007	2,657,096	01/21/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Canada	2,657,107	06/27/2007	2,657,107	01/07/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Canada	2,656,915	06/27/2007	2,656,915	08/07/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
China	200780030939.0	06/27/2007	ZL200780030939.0	08/08/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
China	200780030984.6	06/27/2007	ZL200780030984.6	10/30/2013	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
China	200780031040.0	06/27/2007	ZL200780031040.0	05/30/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Colombia	9007333	06/27/2007	3672		HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Colombia	9007334	06/27/2007	3673		HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Colombia	9007327	06/27/2007	2408	10/29/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong	09108319.8	06/27/2007	1129386	01/22/2016	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong	13112445.1	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong	09108320.5	06/27/2007	1129387B	10/02/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong	13112446	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Hong Kong	09108321.4	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong	15104703.3	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Israel	196128	06/27/2007	196128	11/30/2013	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Israel	196129	06/27/2007	196129	06/25/2013	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Israel	196130	06/27/2007	196130	07/31/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
India	515/DELNP/2009	06/27/2007	280469	02/22/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
India	513/DELNP/2009	06/27/2007	289597	11/15/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
India	512/DELNP/2009	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Indonesia	W00200804210	06/27/2007	IDP000047234	08/09/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Indonesia	W-00200804213	06/27/2007	IDP000045140	03/14/2017	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Indonesia	W-00200804212	06/27/2007	IDP000040030	12/21/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2009-518226	06/27/2007	5232778	03/29/2013	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2013-062411	06/27/2007	5860427	12/25/2015	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2009-518227	06/27/2007	5261383	05/02/2013	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Japan	2013-029649	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2015-178320	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2015-178321	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2017-213854	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2017-213855	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan	2009-518228	06/27/2007	5201740	02/22/2013	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Korea	10-2009-7001678	06/27/2007	1155365	06/05/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Korea	10-2009-7001694	06/27/2007	1179087	08/28/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Korea	2009-7001692	06/27/2007	1157844	06/13/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Mexico	MX/a/2009/000288	06/27/2007	321351	06/24/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Mexico	MX/a/2009/000289	06/27/2007	303155	09/06/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Mexico	MX/a/2009/000290	06/27/2007	279959	10/14/2010	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
New Zealand	574407	06/27/2007	574407	06/05/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

New Zealand	574406	06/27/2007	574406	05/07/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
New Zealand	574405	06/27/2007	574405	05/07/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Philippines	1-2009-500031	06/27/2007	1-2009-500031	01/30/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Philippines	1-2009-500032	06/27/2007	1-2009-500032	05/07/2014	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Philippines	1-2009-500033	06/27/2007	1-2009-500033	07/31/2013	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Russian Federation	2009102516	06/27/2007	2447065	12/10/2011	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Russian Federation	2009102538	06/27/2007	2435763	12/10/2011	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Russian Federation	2009102537	06/27/2007	2430101	09/27/2011	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Singapore	200809619-0	06/27/2007	149161	01/31/2012	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Singapore	200809621-6	06/27/2007	148804	07/29/2011	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Singapore	200809622-4	06/27/2007	148805	07/29/2011	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
South Africa	2009/00559	06/27/2007	2009/00559	06/30/2010	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
South Africa	2009/00492	06/27/2007	2009/00492	06/30/2010	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
South Africa	2009/00558	06/27/2007	2009/00558	04/24/2012	HUMAN PROTEIN TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
United States	61/144,022	01/12/2009			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	61/184,986	06/08/2009			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	14/075,809	11/08/2013			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	15/443,353	02/27/2017			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	16/719,317	12/18/2019			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	15/930,583	05/13/2020			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	13/968,269	08/15/2013			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	13/724,396	12/21/2012	9,096,555	08/04/2015	METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	12/677,512	03/22/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
WO	PCT/US2010/020817	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Europe	10729682.4	01/12/2010	2385763	11/16/2011	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Germany	10729682.4	01/12/2010	2385763	11/16/2011	METHODS FOR TREATING VASCULAR LEAK SYNDROME
France	10729682.4	01/12/2010	2385763	11/16/2011	METHODS FOR TREATING VASCULAR LEAK SYNDROME
United Kingdom	10729682.4	01/12/2010	2385763	11/16/2011	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Austria	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Belgium	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME

Switzerland	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Denmark	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Spain	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Finland	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Ireland	10729682.4	01/12/2010	2385763	s04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Italy	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Netherlands	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Norway	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Poland	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Portugal	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Sweden	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Turkey	10729682.4	01/12/2010	2385763	04/18/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia	2010203352	01/12/2010	2010203352	11/06/2014	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia	2014202211	01/12/2010	2014202211	09/15/2016	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia	2016203254	01/12/2010	2016203254	01/03/2019	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Brazil	PI 1006898-8	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Canada	2,748,814	01/12/2010	2,748,814	02/25/2014	METHODS FOR TREATING VASCULAR LEAK SYNDROME

Canada	2,838,846	01/12/2010	2,838,846	01/19/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
China	201080011867.7	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
China	201810637424.7	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
China	201910044287.0	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Hong Kong	12104707.2	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Indonesia	W00201102787	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Indonesia	P00201900995	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel	214047	01/12/2010	214047	02/01/2017	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel	248340	01/12/2010	248340	12/21/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel	261374	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
India	4961/DELNP/2011	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Japan	2011-545536	01/12/2010	5558489	06/13/2014	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Japan	2014-116250	01/12/2010	5957035	06/24/2016	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Korea	10-2011-7018768	01/12/2010	1495950	02/16/2015	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Malaysia	PI 2011003558	01/12/2010	MY-158804-A	11/15/2016	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Mexico	MX/a/2011/007419	01/12/2010	346984	04/07/2017	METHODS FOR TREATING VASCULAR LEAK SYNDROME
New Zealand	594535	01/12/2010	594535	01/07/2014	METHODS FOR TREATING VASCULAR LEAK SYNDROME

Philippines	1-2011-501369	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Russian Federation	2011133833	01/12/2010	2539917		METHODS FOR TREATING VASCULAR LEAK SYNDROME
Russian Federation	2014146121	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Singapore	201104563-0	01/12/2010	172312	04/19/2017	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Singapore	10201702247S	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
South Africa	2011/05679	01/12/2010	2011/05679	04/25/2012	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Thailand	1101001105	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Vietnam	1-2011-01745	01/12/2010			COMPOUNDS THAT INHIBIT THE INTRACELLULAR CATALYTIC SITE OF PROTEIN TYROSINE PHOSPHATASE BETA (PTP-B) MOLECULE AND COMPOSITIONS COMPRISING THE SAME
United States	61/223,260	07/06/2009			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	13/783,311	03/03/2013	8,883,832	11/11/2014	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	14/272,689	05/08/2014	9,174,950	11/03/2015	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	14/864,462	09/24/2015	9,949,956	04/24/2018	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

United States	15/913,392	03/06/2018			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	16/582,619	09/25/2019			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	12/677,550	12/01/2010	8,569,348	10/29/2013	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
WO	PCT/US2010/020822	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Europe	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Europe	19159755.8	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Germany	10797461.0	01/12/2010	60 2010 057 581.0	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
France	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United Kingdom	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

Austria	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Belgium	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Switzerland	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Denmark	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Spain	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Finland	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Ireland	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Italy	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Netherlands	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

Norway	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Poland	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Portugal	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Sweden	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Turkey	10797461.0	01/12/2010	2451279	03/13/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Australia	2010271105	01/12/2010	2010271105	08/28/2014	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Brazil	PI 1006897-0	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Canada	2,748,765	01/12/2010	2,748,765	07/22/2014	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
China	201080012192.8	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

China	201410144271.4	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
China	201510713404.X	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Hong Kong	12105753.2	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Israel	214048	01/12/2010	214048	03/01/2017	COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
Israel	248514	01/12/2010			COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
India	5406/DELNP/2011	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Indonesia	W00201102788	01/12/2010	IDP000045935	05/18/2017	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2011-554058	01/12/2010	5536113	05/09/2014	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2014-048238	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2015-183047	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR

					PREVENTING METASTASIS OF CANCER CELLS
Japan	2017-80657	01/12/2010	6505153	04/05/2019	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2019-58234	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Korea	2011-7018742	01/12/2010	10-1426125	07/28/2014	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Malaysia	PI 2011003556	01/12/2010	MY-160399-A	03/15/2017	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Mexico	MX/a/2011/007420	01/12/2010	328717	03/20/2015	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
New Zealand	594537	01/12/2010	594537	05/01/2014	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Philippines	1-2011-501370	01/12/2010	1-2011-501370	07/21/2017	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Russian Federation	2011133835	01/12/2010	2519123		COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Singapore	201104564-8	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING

					METASTASIS OF CANCER CELLS
Singapore	10201505672T	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
South Africa	2011/05678	01/12/2010	2011/05678	04/25/2012	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Thailand	1101001097	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Vietnam	1-2011-01744	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	61/390,899	10/07/2010			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
United States	13/253,397	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
United States	14/300,385	01/10/2014			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United States	15/462,326	03/17/2017			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United States	16/513,103	07/16/2019			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA,

					NEOVASCULARIZATION AND RELATED DISEASES
United States	17/352,698	06/21/2021			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United States	15/796,293	10/27/2017			PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES
WO	PCT/US2011/054873	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULARIZATION AND RELATED DISEASES
Europe	11831498.8	10/05/2011	2624916	01/17/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Germany	11831498.8	10/05/2011	2624916	01/17/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
France	11831498.8	10/05/2011	2624916	01/17/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United Kingdom	11831498.8	10/05/2011	2624916	01/17/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Ireland	11831498.8	10/05/2011	2624916	01/17/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Australia	2011312203	10/05/2011	2011312203	11/10/2016	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES

Australia	2016204410	10/05/2011	2016204410	01/17/2019	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Brazil	BR112013008452-9	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Canada	2,818,215	10/05/2011	2,818,215	07/21/2015	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Canada	2,890,554	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
China	201180059165.0	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
China	201610996050.9	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Hong Kong	14101185.7	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Israel	229786	10/05/2011	229786	05/29/2017	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Japan	2013-532904	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES

Japan	2015-182301	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Japan	2015-182302	10/05/2011	6243882	11/17/2017	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Japan	2017-217317	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Korea	10-2013-7011704	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Korea	10-2015-7002121	10/05/2011	1823924	01/25/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Malaysia	PI 2013000970	10/05/2011	MY-176514-A	08/12/2020	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Mexico	MX/a/2013/003890	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Mexico	MX/a/2017/006194	10/05/2011	361520	12/06/2018	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
New Zealand	610230	10/05/2011	610230	11/03/2015	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

New Zealand	705624	10/05/2011	705624	01/05/2017	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Philippines	1-2013-500577	10/05/2011	1-2013-500577	06/14/2019	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Russian Federation	2013120064	10/05/2011	2600794	10/04/2016	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Singapore	2013023809	10/05/2011	189177	11/16/2015	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
South Africa	2013/03005	10/05/2011	2013/03005	01/29/2014	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Thailand	1301001776	10/05/2011			COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
United States	61/792,679	03/15/2013			COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	61/792,868	03/15/2013			COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	61/882,048	09/25/2013			COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	61/882,056	09/25/2013			COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	61/934,570	01/31/2014			COMPOSITIONS AND METHODS FOR

					TREATING OCULAR DISEASES
United States	13/999,670	03/14/2014	9,440,963	09/13/2016	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	14/214,413	03/14/2014			COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/098,955	04/14/2016			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/099,161	04/14/2016			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/355,910	11/18/2016	10,220,048	03/05/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/443,622	02/27/2017			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/958,346	04/20/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/958,355	04/20/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/958,358	04/20/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/969,109	05/02/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	16/257,287	01/25/2019			COMPOSITIONS AND METHODS FOR

					TREATING OCULAR DISEASES
United States	16/559,006	09/03/2019			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	16/888,247	05/29/2020			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	17/155,463	01/22/2021			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
WO	PCT/US2014/0297 23	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Europe	14762974.5	03/14/2014	2967066	10/23/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Europe	19174479.6	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Germany	14762974.5	03/14/2014	602014055 602.7	10/23/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
France	14762974.5	03/14/2014	2967066	10/23/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom	1411935.8	03/14/2014	GB251656 1	03/09/201 6	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom	1520656.8	03/14/2014	2540638	01/17/201 8	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

United Kingdom	1709419.4	03/14/2014	2549865	01/17/2018	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom	14762974.5	14-Mar-2014	2967066	10/23/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Spain	14762974.5	14-Mar-2014	2967066	10/23/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Ireland	14762974.5	03/14/2014	2967066	10/23/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Italy	14762974.5	03/14/2014	2967066	10/23/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Australia	2014233363	03/14/2014	2014233363	10/12/2017	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Australia	2017235953	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Brazil	1120150237533	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Canada	2,903,871	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
China	201480028572.9	03/14/2014	105307498	04/16/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
China	201910221542.4	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR

					TREATING OCULAR DISEASES
Israel	240786	03/14/2014	240786	11/01/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
India	9436/DELNP/2015	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Indonesia	P00201506598	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Israel	267997	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan	2016-503207	03/14/2014	6,572,201	08/16/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan	2019-147238	03/14/2014	6865254	04/07/2021	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan	2021-64106	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Korea	10-2015-7029411	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Malaysia	PI 2015002288	03/14/2014	MY-171945-A	11/08/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Malaysia	PI2019000040	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

Mexico	MX/a/2015/011131	03/14/2014	371382	01/28/2020	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Mexico	MX/a/2020/001060	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
New Zealand	712694	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
New Zealand	750667	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Philippines	1-2015-502153	03/14/2014	1-2015-502153	11/12/2019	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Philippines	1-2019-502018	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Singapore	11201507131W	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
South Africa	2015/07387	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
South Africa	2020/00522	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Thailand	1501005287	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	61/953,680	03/14/2014			HPTP-BETA INHIBITORS

United States	14/657,276	03/14/2014	9,994,560	06/12/2018	HPTP-BETA INHIBITORS
United States	15/972,863	05/07/2018	10,858,354	12/08/2020	HPTP-BETA INHIBITORS
United States	17/062,098	10/02/2020			HPTP-BETA INHIBITORS
WO	PCT/US2015/020425	03/13/2015			HPTP-BETA INHIBITORS
Europe	15760687.2	03/13/2015			HPTP-BETA INHIBITORS
China	201580026210.0	03/13/2015			HPTP-BETA INHIBITORS
Japan	2016-556997	3/13/2015	6483148	02/22/2019	HPTP-BETA INHIBITORS
Japan	2018-246712	3/13/2015	6661744	02/14/2020	HPTP-BETA INHIBITORS
Japan	2019-77696	04/16/2019			HPTP-BETA INHIBITORS
United States	62/034,695	08/07/2014			COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
United States	14/819,871	08/06/2015	9,539,245	01/10/2017	COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
United States	15/365,186	11/30/2016			COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
WO	PCT/US2015/044030	08/06/2015			COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
United States	62/019,002	06/30/2014			METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2
United States	62/190,871	07/10/2015			METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2

United States	62/361,703	07/13/2016			METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2
United States	62/222,481	09/23/2015			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
United States	15/273,068	09/22/2016	10,952,992	03/23/2021	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
United States	17/150,430	01/15/2021			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
WO	PCT/US2016/053107	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Europe	16849594.3	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Australia	2016326510	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Brazil	1120180054992	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Canada	2,998,673	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
China	201680068508.2	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
India	201817014284	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Indonesia	P00201802937	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Israel	258150	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Japan	2018-534502	09/22/2016			METHODS OF TREATING INTRAOCULAR

					PRESSURE WITH ACTIVATORS OF TIE-2
Korea, Republic of	10-2018-7010228	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Malaysia	PI2018000423	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Mexico	MX/a/2018/003542	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
New Zealand	740730	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Philippines	1-2018-500658	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Singapore	11201802402U	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Singapore	10201912000W	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
South Africa	2018/01795	09/22/2016			METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
United States	62/635,102	02/26/2018			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States	62/790,646	01/10/2019			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States	16/284,349	02/25/2019			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States	17/130,687	12/22/2020			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
WO	PCT/US2019/0193 66	02/25/2019			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS

Europe	19756688.8	02/25/2019			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
Japan	2020-567452	02/25/2019			METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States	62/835,626	04/18/2019			METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
United States	62/840,655	04/30/2019			METHODS OF TREATING PULMONARY HYPERTENSION USING TIE-2 ACTIVATORS
United States	16/850,613	04/16/2020			METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
WO	PCT/US2020/028577	04/16/2020			METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
United States	62/865,653	06/24/2019			FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States	63/009,083	04/13/2020			FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States	16/908,996	06/23/2020			FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United Kingdom	2009592.3	06/23/2020			FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States	62/927,233	10/29/2019			SMALL MOLECULE ACTIVATORS OF TIE-2
United States	17/082,612	10/28/2020			SMALL MOLECULE ACTIVATORS OF TIE-2
WO	PCT/US2020/057641	10/28/2020			SMALL MOLECULE ACTIVATORS OF TIE-2
United States	62/840,068	04/29/2019			TIE-2 ACTIVATORS TARGETING SCHLEMM'S CANAL
United States	16/860,347	04/28/2020			TIE-2 ACTIVATORS TARGETING SCHLEMM'S CANAL

WO	PCT/US2020/0302 24	04/28/2020			TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL
United States	62/958,348	01/08/2020			COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
United States	63/089,144	10/08/2020			COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
United States	17/143,394	01/07/2021			COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
WO	PCT/US2021/0124 07	01/07/2021			COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
United States	63/127,412	12/18/2020			DOSAGE FORMS OF TIE-2 ACTIVATORS
United States	63/127,411	12/18/2020			METHODS FOR MANUFACTURE OF SMALL ACTIVATORS OF TIE-2
United States	63/028,317	05/21/2020			METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2
WO	PCT/US2021/0334 95	05/20/2021			METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2

ATTACHMENT B

Country	Application No.	Filing Date	Patent No.	Patent Date	Title
United States	60/790,506	04/07/2006			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	60/798,896	05/09/2006			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	11/784,094	04/05/2007	7,973,142	07/05/2011	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	15/430,100	02/10/2017	9,926,367	03/27/2018	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	15/894,442	02/12/2018			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	16/696,212	11/26/2019			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	16/784,970	02/07/2020			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
United States	13/115,180	05/25/2011	8,524,235	09/03/2013	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	13/958,990	08/05/2013			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)

WO	PCT/IB2007/05123 9	04/05/200 7			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
Europe	07735408.2	04/05/200 7			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Europe	11155518.1	04/05/200 7	2371865	07/12/201 7	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Europe	17169315.3	04/05/201 7	3252079	07/29/202 0	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United Arab Emirates	978/2008	04/05/200 7			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Austria	11155518.1	04/05/200 7	2371865	07/12/201 7	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Australia	2007237096	04/05/200 7	200723709 6	12/20/201 2	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Belgium	11155518.1	04/05/200 7	2371865	07/12/201 7	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Brazil	PI 0710645-9	04/05/200 7			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

Canada	2,648,284	04/05/2007	2,648,284	08/16/2016	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Switzerland	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
China	200780011778.0	04/05/2007	ZL 200780011778.0	08/31/2016	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
China	201610648805.6	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Colombia	08-105786	04/05/2007	4311	08/24/2012	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Germany	602007051642.0	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Germany	602007060503.2	04/05/2017	3252079	07/29/2020	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Denmark	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Egypt	1612/2008	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

Spain	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Spain	17169315.3	04/05/2017	3252079	07/29/2020	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Finland	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
France	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
France	17169315.3	04/05/2017	3252079	07/29/2020	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United Kingdom	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United Kingdom	17169315.3	04/05/2017	3252079	07/29/2020	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Indonesia	W00200803006	04/05/2007	IDP000051812	07/10/2018	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Ireland	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

Israel	194550	04/05/2007	194550	10/01/2015	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Israel	239320	04/05/2007	239320	05/01/2019	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Israel	263755	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
India	8043/DELNP/2008	04/05/2007	271047	01/29/2016	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Italy	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Italy	17169315.3	04/05/2017	3252079	07/29/2020	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan	2009-503719	04/05/2007	5166398	12/28/2012	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan	2012-223157	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan	2015-107275	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

Japan	2016-226664	04/05/2007	6395791	09/07/2018	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan	2017-131042	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan	2018-246735	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Korea	10-2008-7026944	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Korea	10-2011-7024995	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Korea	10-2013-7022106	04/05/2007	1482483	01/07/2015	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Morocco	PV/31325	04/05/2007	30353	04/01/2009	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Mexico	MX/a/2008/012991	04/05/2007	295062	01/23/2012	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Malaysia	PI 20080003870	04/05/2007	MY-150400-A	01/15/2014	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

Netherlands	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
New Zealand	571300	04/05/2007	571300	04/02/2012	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Philippines	1-2008-502246	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Poland	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Portugal	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Russia	2008138399	04/05/2007	2473565	01/27/2013	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Russia	2011141686	04/05/2007	2494108	09/27/2013	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Sweden	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Singapore	200806979-1	04/05/2007			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

Singapore	201102498-1	04/05/2007	170842	04/09/2015	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
San Marino	P-200800060	04/05/2007	SM-AP-200800060		ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Turkey	11155518.1	04/05/2007	2371865	07/12/2017	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Vietnam	1-2008-02466	04/05/2007	14457	08/17/2015	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
South Africa	2008/07978	04/05/2007	2008/07978	08/26/2009	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	61/546,708	10/13/2011			TREATMENT OF OCULAR DISEASE
United States	13/652,154	10/15/2012	8,999,325	04/07/2015	TREATMENT OF OCULAR DISEASE
United States	14/627,463	02/20/2015			TREATMENT OF OCULAR DISEASES
United States	15/463,340	03/20/2017	10,329,357	06/25/2019	TREATMENT OF OCULAR DISEASES
United States	16/395,972	04/26/2019			TREATMENT OF OCULAR DISEASES
United States	16/751,824	01/24/2020			TREATMENT OF OCULAR DISEASES
WO	PCT/US2012/060263	10/15/2012			TREATMENT OF OCULAR DISEASE
Europe	12840725.1	10/15/2012	2766044	12/11/2019	TREATMENT OF OCULAR DISEASE

Europe	18202143.6	10/15/2012			TREATMENT OF OCULAR DISEASE
Australia	2012323849	10/15/2012	2012323849	08/03/2017	TREATMENT OF OCULAR DISEASE
Brazil	112014008759-8	10/15/2012			TREATMENT OF OCULAR DISEASE
Canada	2,850,824	10/15/2012			TREATMENT OF OCULAR DISEASE
China	201280054482.8	10/15/2012			TREATMENT OF OCULAR DISEASE
China	201710084072.2	10/15/2012			TREATMENT OF OCULAR DISEASE
Germany	12840725.1	10/15/2012	602012066453.3	12/11/2019	TREATMENT OF OCULAR DISEASE
Spain	12840725.1	10/15/2012	2766044	12/11/2019	TREATMENT OF OCULAR DISEASE
France	12840725.1	10/15/2012	2766044	12/11/2019	TREATMENT OF OCULAR DISEASE
United Kingdom	12840725.1	10/15/2012	2766044	12/11/2019	TREATMENT OF OCULAR DISEASE
Hong Kong	15101784.1	10/15/2012			TREATMENT OF OCULAR DISEASE
Hong Kong	15101828.9	10/15/2012			TREATMENT OF OCULAR DISEASE
Ireland	12840725.1	10/15/2012	2766044	12/11/2019	TREATMENT OF OCULAR DISEASE
Italy	12840725.1	10/15/2012	2766044	12/11/2019	TREATMENT OF OCULAR DISEASE
Japan	2014-535978	10/15/2012			TREATMENT OF OCULAR DISEASE
Japan	2016-178592	10/15/2012	6259503	12/15/2017	TREATMENT OF OCULAR DISEASE
Japan	2016-178593	10/15/2012			TREATMENT OF OCULAR DISEASE

Japan	2018-103592	10/15/2012			TREATMENT OF OCULAR DISEASE
Japan	2018-103593	10/15/2012			TREATMENT OF OCULAR DISEASE
Mexico	MX/a/2014/004449	10/15/2012	347226	04/19/2017	TREATMENT OF OCULAR DISEASE
New Zealand	623275	10/15/2012	623275	08/30/2016	TREATMENT OF OCULAR DISEASE
United States	61/546,697	10/13/2011			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	61/546,748	10/13/2011			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	13/652,203	10/15/2012			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	15/438,218	02/21/2017	10,150,811	12/11/2018	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	16/168,060	10/23/2018	10,815,300	10/27/2020	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	17/027,034	09/21/2020			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
WO	PCT/US2012/060273	10/15/2012			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Europe	12840220.3	10/15/2012			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Europe	18201774.9	10/15/2012			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Australia	2012323856	10/15/2012	2012323856	09/07/2017	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Brazil	112014008819-5	10/15/2012			METHODS FOR TREATING VASCULAR

					LEAK SYNDROME AND CANCER
Canada	2,850,830	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
China	201280052307.5	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
China	201910768287.5	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Hong Kong	15101641.4	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan	2014-535979	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan	2017-130652	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan	2017-143622	07/25/201 7			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan	2019-87483	10/15/201 2	6706367	05/19/202 0	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan	2019-115666	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Mexico	MX/a/2014/004448	10/15/201 2	363351	03/20/201 9	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Mexico	MX/a/2019/002983	10/15/201 2			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
New Zealand	623283	10/15/201 2	623283	08/30/201 6	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	62/054,752	24-Sep- 2014			VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY

United States	14/862,948	09/23/2015			VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
United States	15/815,097	11/16/2017			VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
WO	PCT/US2015/051719	09/23/2015			VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
United States	62/364,381	07/20/2016			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
United States	62/377,072	08/19/2016			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
United States	15/654,289	07/19/2017	10,253,094	04/09/2019	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP (HPTP-Beta)
United States	16/180,850	11/05/2018	10,604,569	03/31/2020	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
United States	16/180,854	11/05/2018	10,597,452	03/24/2020	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
United States	16/775,860	01/29/2020			HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
United States	16/851,420	04/17/2020			HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
Europe	17831790.5	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
WO	PCT/US2017/042855	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP

Australia	2017299581	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Brazil	1120190012060	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Canada	3,030,298	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
China	201780057896.9	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Indonesia	PID201900449	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Israel	263936	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
India	201817049429	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Japan	2019-502696	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Japan	2020-120521	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP (HPTP- β)
Korea	10-2019-7002479	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Mexico	MX/a/2019/000727	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Malaysia	PI2019000120	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
New Zealand	749494	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP

Philippines	1-2019-500145	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Singapore	11201900464T	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Singapore	10201912556V	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
South Africa	2019/00368	07/19/2017			HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
South Africa	2020/01991	07/19/2017			HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-β)

ATTACHMENT C

Country	Application No.	Filing Date	Patent No.	Patent Date	Title
United States	62/735,331	09/24/2018			BISPECIFIC ANTIBODIES THAT TARGET VE-PTP (HPTP-B) AND VEGF
United States	62/832,461	04/11/2019			MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
United States	16/579,078	09/23/2019	10,894,824	01/19/2021	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
United States	17/117,993	12/10/2020			MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
WO	PCT/US2019/052405	09/23/2019			MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
Europe	19867311.3	09/23/2019			MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
China	201980077336.9	09/23/2019			MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF

Japan	2021-516373	09/23/2019			MULTISPECIFIC ANTIBODIES THAT TARGET HPTP- β (VE-PTP) AND VEGF
-------	-------------	------------	--	--	---

ACTIVE/111122520.9

RECORDED: 09/09/2021

**PATENT
REEL: 057448 FRAME: 0098**